Scholarlink

<p>FDA-approved Prussian blue (PB) has been developed as a nano photothermal therapy (PTT) agent due to its unique Fe<sup>III</sup>-CN-Fe<sup>II</sup> structure and the resulting near-infrared (NIR) absorption performance. Nevertheless, the NIR absorption peaks of traditional PB-based nanomedicines are often located in the NIR-I region (700–900&#xa0;nm) rather than NIR-II region (900–1700&#xa0;nm), thus limiting their efficacy in treating deep lesions. Herein, curcumin (Cur)-functionalized PB nanomedicine is elaborately designed for NIR-II PTT against bacterial infections. In addition to serving as a dispersant and a reducing agent, the introduced Cur effectively regulates the absorption peak of PB to the NIR-II region. Moreover, as-prepared Cur-functionalized PB nanomedicine demonstrated superior photothermal antibacterial performance against S. aureus. Therefore, this study proffers a new attempt centered on the optical performance regulation of PB and lays the foundation for next-generation PTT nanomedicines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Curcumin-functionalized Prussian blue for NIR-II photothermal antibacterial therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Zhouhua Li,
  • Guanhua Sun,
  • Fei Ge,
  • Yuanyuan Shen,
  • Xiuying Yang,
  • Bing Yao,
  • Caixia Yu,
  • Shihong Su,
  • Junlie Yao,
  • Yong Wang

摘要

FDA-approved Prussian blue (PB) has been developed as a nano photothermal therapy (PTT) agent due to its unique FeIII-CN-FeII structure and the resulting near-infrared (NIR) absorption performance. Nevertheless, the NIR absorption peaks of traditional PB-based nanomedicines are often located in the NIR-I region (700–900 nm) rather than NIR-II region (900–1700 nm), thus limiting their efficacy in treating deep lesions. Herein, curcumin (Cur)-functionalized PB nanomedicine is elaborately designed for NIR-II PTT against bacterial infections. In addition to serving as a dispersant and a reducing agent, the introduced Cur effectively regulates the absorption peak of PB to the NIR-II region. Moreover, as-prepared Cur-functionalized PB nanomedicine demonstrated superior photothermal antibacterial performance against S. aureus. Therefore, this study proffers a new attempt centered on the optical performance regulation of PB and lays the foundation for next-generation PTT nanomedicines.